Perrigo Company plc
General ticker "PRGO" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $3.5B (TTM average)
Perrigo Company plc does not follow the US Stock Market performance with the rate: -17.1%.
Estimated limits based on current volatility of 1.6%: low 13.56$, high 14.14$
Factors to consider:
- Company pays dividends (quarterly): last record date 2025-08-29, amount 0.29$ (Y8.60%)
- Total employees count: 8379 (-8.3%) as of 2024
- US accounted for 60.7% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Cybersecurity threats, Market competition, Regulatory and compliance, Economic downturns and volatility, Supply chain disruptions
- Current price 18.4% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [16.54$, 30.63$]
- 2025-12-31 to 2026-12-31 estimated range: [15.29$, 28.56$]
Financial Metrics affecting the PRGO estimates:
- Positive: with PPE of 10.0 at the end of fiscal year the price was neutral
- Positive: -3.60 < Operating profit margin, % of 2.59
- Negative: negative Industry operating cash flow (median)
- Positive: -2.95 < Return on assets ratio (scaled to [-100,100]) of -1.64
- Positive: Industry inventory ratio change (median), % of -1.41 <= -0.15
- Positive: 6.82 < Operating cash flow per share per price, % of 10.30
- Positive: Inventory ratio change, % of 0.17 <= 0.84
- Positive: 41.86 < Shareholder equity ratio, % of 44.77 <= 63.39
Short-term PRGO quotes
Long-term PRGO plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $4,450.80MM | $4,656.40MM | $4,367.40MM |
| Operating Expenses | $4,371.90MM | $4,504.50MM | $4,254.50MM |
| Operating Income | $78.90MM | $151.90MM | $112.90MM |
| Non-Operating Income | $-218.00MM | $-160.20MM | $-193.60MM |
| Interest Expense | $156.00MM | $173.80MM | $187.80MM |
| R&D Expense | $123.10MM | $122.50MM | $112.20MM |
| Income(Loss) | $-139.10MM | $-8.30MM | $-80.70MM |
| Taxes | $-8.20MM | $-3.90MM | $80.00MM |
| Other Income(Loss) | $-9.70MM | $-8.30MM | $-11.10MM |
| Profit(Loss)* | $-130.90MM | $-21.00MM | $-182.90MM |
| Stockholders Equity | $4,842.10MM | $4,767.90MM | $4,319.40MM |
| Inventory | $1,150.30MM | $1,140.90MM | $1,081.80MM |
| Assets | $11,017.30MM | $10,809.10MM | $9,647.70MM |
| Operating Cash Flow | $307.30MM | $405.50MM | $362.90MM |
| Capital expenditure | $96.40MM | $101.70MM | $118.30MM |
| Investing Cash Flow | $-1,958.60MM | $-77.50MM | $78.80MM |
| Financing Cash Flow | $421.60MM | $-187.20MM | $-611.00MM |
| Earnings Per Share** | $-0.97 | $-0.16 | $-1.33 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.